首页 › 滤泡性淋巴瘤 › 犹他州 › Salt Lake City
Salt Lake City UT 滤泡性淋巴瘤临床试验
13项针对 滤泡性淋巴瘤的研究正在 Salt Lake City及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
招募中3 期
- Huntsman Cancer Institute/University of Utah, Salt Lake City
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
招募中1 期
- Intermountain Healthcare, Salt Lake City
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
招募中1/2 期
- Huntsman Cancer Institute, Salt Lake City
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
招募中3 期
- Research Site, Salt Lake City
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
招募中3 期
- Huntsman Cancer Institute - Oncology Division, Salt Lake City
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
招募中1 期
- Huntsman Cancer Institute/University of Utah, Salt Lake City
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
招募中3 期
- Huntsman Cancer Insititute, University of Utah, Salt Lake City
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
招募中1/2 期
- Huntsman Cancer Institute, Salt Lake City
- Intermountain Healthcare, Salt Lake City
Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder
招募中2 期
- University of Utah, Salt Lake City
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
招募中1 期
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
招募中1 期
- Huntsman Cancer Institute, University of Utah, Salt Lake City
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
招募中1/2 期
- University of Utah, Salt Lake City
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中观察性研究
- Massive Bio SYNERGY-AI site, Salt Lake City
其他城市的 滤泡性淋巴瘤试验
- New York City, NY24 项研究
- Milwaukee, WI19 项研究
- Nashville, TN18 项研究
- Houston, TX18 项研究
- Boston, MA17 项研究
- Baldwin Park, CA16 项研究
- Seattle, WA15 项研究
- Durham, NC15 项研究
- Columbus, OH13 项研究
- Chicago, IL12 项研究
- San Antonio, TX12 项研究
- Philadelphia, PA12 项研究
Salt Lake City的其他研究
- 非小细胞肺癌31 项研究
- 癌症（所有类型）27 项研究
- 乳腺癌27 项研究
- 结直肠癌22 项研究
- 肺癌21 项研究
- 黑色素瘤21 项研究
- 多发性骨髓瘤21 项研究
- 转移性癌症20 项研究
- 卵巢癌19 项研究
- 肥胖症18 项研究
- 急性髓系白血病17 项研究
- 心力衰竭17 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。